Drug & intervention

midazolam

RxCUI 6960

Clinical trials54
Recruiting3
Related conditions20
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…
Background context

Midazolam

Midazolam, sold under the brand name Versed among others, is a benzodiazepine medication used for anesthesia, premedication before surgical anesthesia, and procedural sedation, and to treat severe agitation. It induces sleepiness, decreases anxiety, and causes anterograde amnesia. The drug does not cause an individual to become unconscious, merely to be sedated. It is also useful for the treatment of prolonged (lasting over five minutes) seizures. Midazolam can be given by mouth, intravenously, by injection into a muscle, by spraying into the nose, or through the cheek. When given intravenously, it typically begins working within five minutes; when injected into a muscle, it can take fifteen minutes to begin working; when taken orally, it can take 10–20 minutes to begin working. Side effects can include a decrease in efforts to breathe, low blood pressure, and sleepiness. Tolerance to its effects and withdrawal syndrome may occur following long-term use. Paradoxical effects, such as increased activity, can occur especially in children and older people. There is evidence of risk when used during pregnancy but no evidence of harm with a single dose during breastfeeding. Midazolam was patented in 1974 and came into medical use in 1982. It is on the World Health Organization's List of Essential Medicines. Midazolam is available as a generic medication. In many countries, it is a controlled substance.

Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

40 shown
A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and WarfarinNCT07331389 · 2025-09-24
RECRUITING
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS MutationsNCT06835569 · 2025-03-05
RECRUITING
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination TherapyNCT05646862 · 2023-06-07
RECRUITING
Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult ParticipantsNCT07235748 · 2025-10-07
COMPLETED
A Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe SubstratesNCT06632990 · 2024-11-04
ACTIVE_NOT_RECRUITING
A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or ObesityNCT06564441 · 2024-10-01
COMPLETED
A Study of Calderasib (MK-1084) With Midazolam and Digoxin in Healthy Participants (MK-1084-009)NCT06575933 · 2024-09-03
COMPLETED
A Study to Investigate the Pharmacokinetics of Midazolam After Repeated Doses of Camizestrant (AZD9833) and to Investigate the Pharmacokinetics of Camizestrant When Administered Alone and in Combination With Carbamazepine in Healthy Post-Menopausal Female ParticipantsNCT06547164 · 2024-08-27
COMPLETED
A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy ParticipantsNCT06360211 · 2024-04-17
COMPLETED
A Study to Learn How Different Amounts of PF-06954522 Are Tolerated and Act in Adults With Type 2 Diabetes MellitusNCT06279234 · 2024-02-20
COMPLETED
ECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy ParticipantsNCT06293742 · 2024-02-08
COMPLETED
A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese ParticipantsNCT06186622 · 2024-01-02
COMPLETED
A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese ParticipantsNCT05445232 · 2022-07-08
COMPLETED
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.NCT05355701 · 2022-07-05
ACTIVE_NOT_RECRUITING
A Study to Assess the Effect of AZD5462 on the Pharmacokinetics of Midazolam, Rosuvastatin and DigoxinNCT05395117 · 2022-06-30
COMPLETED
Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female VolunteersNCT05438303 · 2022-06-13
COMPLETED
A Study of LY3549492 in Participants With Type 2 Diabetes Mellitus (T2DM)NCT05327595 · 2022-05-09
COMPLETED
A Study to Assess S-309309 in Healthy and Obese ParticipantsNCT05247970 · 2022-01-04
COMPLETED
Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced DyskinesiaNCT04912115 · 2021-10-05
SUSPENDED
CYP3A4 Activity in Patients With Prostate Cancer Versus Male Patients With Other Solid TumoursNCT05518799 · 2021-04-22
COMPLETED
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain InvolvementNCT04543188 · 2021-01-08
TERMINATED
Study To Evaluate The Effect Of Two Steady State Doses of PF 06882961 On Rosuvastatin And Midazolam Pharmacokinetics In Otherwise Healthy Adult Participants With ObesityNCT04621227 · 2020-12-15
COMPLETED
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid TumorsNCT04557449 · 2020-09-23
ACTIVE_NOT_RECRUITING
Metformin's Effect on Drug Metabolism in Patients With Type 2 DiabetesNCT04504045 · 2020-09-01
TERMINATED
Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)NCT04051827 · 2019-12-23
COMPLETED
Does Type of Anesthesia Influence Inflammation Change After Breast Surgery?NCT04172220 · 2019-10-31
COMPLETED
A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the BodyNCT03955939 · 2019-08-02
COMPLETED
A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid TumorsNCT03420742 · 2019-06-26
COMPLETED
A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or RosuvastatinNCT03970798 · 2019-05-22
COMPLETED
Effect of Obesity on Proton Pump InhibitorsNCT04248335 · 2018-07-03
COMPLETED
Preoxygenation With Optiflow™ in Morbidly Obese Patients is Superior to Face MaskNCT03009877 · 2018-07-01
WITHDRAWN
Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate CancerNCT03436485 · 2018-03-19
ACTIVE_NOT_RECRUITING
Drug-drug-interaction Study to Assess the Effect of Darolutamide on the Pharmacokinetics of Probe Substrates of CYP3A4 and P-gp in Healthy Male VolunteersNCT03237416 · 2017-08-02
COMPLETED
PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast SurgeryNCT03084536 · 2017-06-07
COMPLETED
A Drug to Drug Interaction Study of Sotagliflozin With Midazolam and MetoprololNCT02940379 · 2016-10-01
COMPLETED
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic CancerNCT02857270 · 2016-09-29
COMPLETED
Clinical Trial to Examine Individual Pain Tolerance in the Use of Two Anesthetic Techniques to Perform Saturation Prostate BiopsyNCT02909049 · 2016-04-01
COMPLETED
A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced TumorsNCT02422589 · 2015-10-23
COMPLETED
A Study to Assess Effect of JNJ-54861911 on Pharmacokinetics of Cocktail Representatives for Cytochrome P450 (CYP) 3A4, CYP2B6, CYP2C9, and CYP1A2 SubstratesNCT02211079 · 2014-09-01
COMPLETED
A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) MutationsNCT02113813 · 2014-04-09
COMPLETED

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.